Compound library

Understand what people are taking.

Browse medicines, supplements, herbs, and health foods. Each profile brings community reports and linked research into one clear view.

supplement × Metabolic Health

NMN / NR (NAD+ precursors) for Blood Sugar Control

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are forms of vitamin B3 that the body turns into NAD+. The biochemical effect is proven: oral doses reliably raise blood NAD+. Clinical benefit in humans is not. Meta-analyses of randomised trials find no improvement in blood sugar, insulin, cholesterol, muscle mass or strength, and only a small diastolic blood-pressure signal so far.

-no reports yet

-avg rating

-would recommend

On this pageWhat studies found Overview Evidence Community outcomes Related

What studies found

NMN / NR (NAD+ precursors) for Blood Sugar Control

3 of 21 results reported a benefit, from 4 published studies.

4 studies, including a review of trials

3 reported a benefit
18 no clear benefit

Fasting blood sugarNo clear benefit foundNMN supplementation did not significantly improve fasting glucose with no comparator reported; the difference versus the comparator was not statistically established in 513.2 reviews of trials · no comparable figure reported0 of 2 results reported a benefit2025 study ↗
Long-term blood sugar (HbA1c)No clear benefit foundmeasurement not reportedNicotinamide mononucleotide did not significantly improve glycated hemoglobin with no comparator reported in 342 (14 days to 12 weeks).1 review of trials2024 study ↗
Blood fats (general)No clear benefit foundmeasurement not reportedNicotinamide mononucleotide did not significantly improve lipid profile with no comparator reported in 342 (14 days to 12 weeks).1 review of trials2024 study ↗
Triglycerides (blood fats)No clear benefit foundmeasurement not reportedNMN supplementation did not significantly improve triglycerides with no comparator reported; the difference versus the comparator was not statistically established in 513.1 review of trials2025 study ↗
'Bad' (LDL) cholesterolNo clear benefit foundmeasurement not reported

9 laboratory markers also measured

Blood NAD+ levels · lab markerReported a benefitmeasurement not reportedNMN supplementation improved blood NAD levels with no comparator reported in 513.1 review of trials2025 study ↗
Fasting insulin · lab markerNo clear benefit foundmeasurement not reportedNicotinamide mononucleotide did not significantly improve fasting insulin with no comparator reported in 342 (14 days to 12 weeks).1 review of trials2024 study ↗
Insulin resistance · lab markerNo clear benefit foundmeasurement not reportedNicotinamide mononucleotide did not significantly improve homeostatic model assessment for insulin resistance with no comparator reported in 342 (14 days to 12 weeks).1 review of trials2024 study ↗
Insulin sensitivity (glucose disposal) · lab markerMixed results2 randomised trials · no comparable figure reported1 of 2 results reported a benefit2018 study ↗
Fat breakdown (lipolysis) · lab markerNo clear benefit found

These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every individual result is listed below.

See every result

Why NMN / NR (NAD+ precursors) for Blood Sugar Control?

The connection

Insulin resistance, pre-diabetes, type 2 diabetes, and metabolic syndrome.

Also known as: NMN, Nicotinamide mononucleotide, NR, Nicotinamide riboside

Evidence analytics

NMN / NR (NAD+ precursors) × Blood Sugar Control: at a glance

Every published result for this pair, extracted and audited.

These charts group published studies by what they reported and how they were run — green marks studies that reported a benefit for this pairing. Tiers run from pooled analyses of many trials (strongest) to one-off observational reports.

What the evidence shows

Direction of reported outcomes for NMN / NR (NAD+ precursors) in blood sugar control.

Benefit
No benefit

Evidence quality mix

Study designs behind these findings.

Systematic review
Meta-analysis
Randomised trial

Studies

Reviews & meta-analyses

RCT findings

5,108

Participants (where reported)

Peer-reviewed research

NMN / NR (NAD+ precursors) × Blood Sugar Control: the evidence base

Hand-selected PubMed studies, linked to the originals.

6studies referenced

5journals

2023–2026publication range

Ordered by strength of evidence, then result direction.

01Adjunctive berberine for schizophrenia with metabolic syndrome: a systematic review and meta-analysisXie K, et al. · Frontiers in psychiatry · 2026PMID 42433212 ↗02The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled TrialsNazari A, et al. · Clinical therapeutics · 2024PMID 38016844 ↗03Effect of Fenugreek on Hyperglycemia: A Systematic Review and Meta-AnalysisShabil M, et al. · Medicina (Kaunas, Lithuania) · 2023PMID 36837450 ↗04Effect of saffron and fenugreek on lowering blood glucose: A systematic review with meta-analysisCorreia AGDS, et al. · Phytotherapy research : PTR · 2023PMID 36992660 ↗

Community outcomes

No community reports yet for NMN / NR (NAD+ precursors) for blood sugar control.

Be the first to share what you noticed with NMN / NR (NAD+ precursors) for blood sugar control. Why counts start empty.

Share an outcome

Important: This page reflects observational, aggregate-only community reporting and independent published research. It is not medical advice, and it does not claim any compound treats, cures, or is effective for any condition. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or treatment.

Study results, as reported by the publications

Every measured outcome, one row per finding - numbers exactly as reported.

Study	Design	n	Duration	Outcome measured	Reported result	Direction
PMID 39116016 2025	Systematic review	513	-	blood NAD levels	reported qualitatively	Benefit
PMID 39116016 2025	Systematic review	513	-	fasting glucose	reported qualitatively	No benefit
PMID 39116016 2025	Systematic review	513	-	HDL-C	reported qualitatively	No benefit
PMID 39116016 2025	Systematic review	513	-	LDL-C	reported qualitatively	No benefit
PMID 39116016 2025	Systematic review	513	-	total cholesterol	reported qualitatively	No benefit
PMID 39116016 2025	Systematic review	513	-	triglycerides	reported qualitatively	No benefit
PMID 39531138 2024	Meta-analysis	342	14 days to 12 weeks	fasting glucose	reported qualitatively	No benefit
PMID 39531138 2024	Meta-analysis	342	14 days to 12 weeks	fasting insulin	reported qualitatively	No benefit
PMID 39531138 2024	Meta-analysis	342	14 days to 12 weeks	glycated hemoglobin	reported qualitatively	No benefit
PMID 39531138 2024	Meta-analysis	342	14 days to 12 weeks	homeostatic model assessment for insulin resistance	reported qualitatively	No benefit
PMID 39531138 2024	Meta-analysis	342	14 days to 12 weeks	lipid profile	reported qualitatively	No benefit
PMID 33888596 2021	Randomised trial	-	10-week	Insulin-stimulated glucose disposal (hyperinsulinemic-euglycemic clamp)	reported qualitatively	Benefit
PMID 33888596 2021	Randomised trial	-	10-week	Skeletal muscle insulin signaling (phosphorylation of AKT and mTOR)	reported qualitatively	Benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Body composition	reported qualitatively	No benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Endogenous glucose production	reported qualitatively	No benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Glucose disposal and oxidation	reported qualitatively	No benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Insulin sensitivity	reported qualitatively	No benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Intrahepatic lipid content	reported qualitatively	No benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Lipolysis	reported qualitatively	No benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Oxidation of lipids	reported qualitatively	No benefit
PMID 29992272 2018	Randomised trial	40	12 wk	Resting energy expenditure	reported qualitatively	No benefit

Understand what people are taking.

NMN / NR (NAD+ precursors) for Blood Sugar Control

NMN / NR (NAD+ precursors) for Blood Sugar Control

The connection

NMN / NR (NAD+ precursors) × Blood Sugar Control: at a glance

What the evidence shows

Evidence quality mix

NMN / NR (NAD+ precursors) × Blood Sugar Control: the evidence base

No community reports yet for NMN / NR (NAD+ precursors) for blood sugar control.

Go deeper

Study results, as reported by the publications